AIRMESS – Academy of International Regenerative Medicine &amp; Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous stem cell-based therapy (ASC-BT) in androgenetic alopecia and wound healing

Gentile, Pietro; Alves, Rubina; Cole, John P.; Andjelkov, Katarina; Helmelryck, Thierry Van; Fernandez, J.; Trivisonno, Angelo; Guillaume, Lemierre; Verpaele, Alexis; Tonnard, Patrick; Magalon, Jérémy; Magalon, G.; Menkes, Sophie

doi:10.1080/14712598.2021.1908995

Cited by 22 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, combined PRP and human follicle MSCs positively influenced hair growth, stimulated hair follicle development, and suppressed apoptosis [ 84 ]. Of note, Gentile et al provided an evidence of therapeutic positive outcomes of autologous stem cell-based therapy including PRP, human follicle stem cells, and adipose-derived stem cells in wound healing and hair regrowth [ 85 ]. PRP was also applied in oral and maxillofacial surgery [ 86 ].…”

Section: Discussionmentioning

confidence: 99%

Adipose mesenchymal stem cells combined with platelet-rich plasma accelerate diabetic wound healing by modulating the Notch pathway

et al. 2021

View full text Add to dashboard Cite

Background Diabetic foot ulceration is a serious chronic complication of diabetes mellitus characterized by high disability, mortality, and morbidity. Platelet-rich plasma (PRP) has been widely used for diabetic wound healing due to its high content of growth factors. However, its application is limited due to the rapid degradation of growth factors. The present study aimed to evaluate the efficacy of combined adipose-derived mesenchymal stem cells (ADSCs) and PRP therapy in promoting diabetic wound healing in relation to the Notch signaling pathway. Methods Albino rats were allocated into 6 groups [control (unwounded), sham (wounded but non-diabetic), diabetic, PRP-treated, ADSC-treated, and PRP+ADSCs-treated groups]. The effect of individual and combined therapy was evaluated by assessing wound closure rate, epidermal thickness, dermal collagen, and angiogenesis. Moreover, gene and protein expression of key elements of the Notch signaling pathway (Notch1, Delta-like canonical Notch ligand 4 (DLL4), Hairy Enhancer of Split-1 (Hes1), Hey1, Jagged-1), gene expression of angiogenic marker (vascular endothelial growth factor and stromal cell-derived factor 1) and epidermal stem cells (EPSCs) related gene (ß1 Integrin) were assessed. Results Our data showed better wound healing of PRP+ADSCs compared to their individual use after 7 and 14 days as the combined therapy caused reepithelialization and granulation tissue formation with a marked increase in area percentage of collagen, epidermal thickness, and angiogenesis. Moreover, Notch signaling was significantly downregulated, and EPSC proliferation and recruitment were enhanced compared to other treated groups and diabetic groups. Conclusions These data demonstrated that PRP and ADSCs combined therapy significantly accelerated healing of diabetic wounds induced experimentally in rats via modulating the Notch pathway, promoting angiogenesis and EPSC proliferation.

show abstract

Section: Discussionmentioning

confidence: 99%

Adipose mesenchymal stem cells combined with platelet-rich plasma accelerate diabetic wound healing by modulating the Notch pathway

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…An expert opinion on the effects of PRP and autologous stem cell therapy noted that hair regeneration and wound healing share many common molecular pathways, especially the stimulation of Wnt/b-catenin signalling [26], that are similarly influenced by ALRV5XR. A meta-analysis of clinical trials of PRP in men and women found a mean efficacy of change in total hair count of 23.5 (95%CI: 9.9À37.1) hairs/cm 2 , however within 9À12 months of completing PRP or stem cell therapy, the gains in hair density decline by approximately 50% [16,26]. When considering the initial rapid hair regrowth effect followed by a decline in hair density after PRP and stem cell therapy [23,26], studying the use of ALRV5XR as an adjuvant for pre and post PRP or stem cell therapy, may offer a potentiating effect to enhance or sustain the hair density improvement.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, increasing VEGF signalling to enhance blood flow to HFs, which is linked to the promotion of hair growth is relevant for attainment of a healthy hair physiology [13,14]. Similarly the regulation of additional growth factors such as FGF-7, FGF-18, HGF, IGF, KGF, and cytokines such as mTORC1, PKC, PPARg, Shh, COX, INFa, INF-g, Interleukins 1b, 6 and 12, NF-k b, Prostaglandin D2, TGF-b, and TNF-a [13,26] are likely to be influenced at least indirectly by several of the ingredients of ALRV5XR. We demonstrated that ALRV5XR vs. placebo has a clinically significant TH regrowth effect in women with AGA or TE over 24 weeks, where absolute TH density improved by 30¢1 THs/cm 2 (p = 0¢0002), and relative TH density increased by 19¢7% (p = 0¢0016) [27].…”

Section: Added Value Of This Studymentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial

Feldman¹,

Fiebig²,

Piwko

et al. 2021

EClinicalMedicine

View full text Add to dashboard Cite

Background: Androgenetic alopecia (AGA) is the most common hair loss disorder seen in men. It can have an early onset but has also been associated with ageing and senescence. It often induces pronounced psychological impact. ALRV5XR, a new hair loss treatment herein evaluated, was designed to target multiple molecular pathways involved in hair growth and hair follicle stem cell biology. The main objectives of the study were the assessment of safety and efficacy profiles of ALRV5XR in men. Methods: This 24-week, parallel randomised, placebo-controlled, double-blinded clinical trial was performed in a USA community clinic. Healthy men (age 22À65) with AGA and belonging to the Hamilton-Norwood (HN) classification IÀVII and Fitzpatrick skin type (FST) IÀVI, were randomly allocated in a 1:1 ratio into ALRV5XR or placebo treatment groups. Dermatologist assessment, phototrichograms, and blood samples were obtained in a blinded fashion at baseline, 12 and 24 weeks. Subjects were given a masked treatment consisting of oral capsules, shampoo, conditioner, and follicle serum, which was intended for daily use. Efficacy was assessed via absolute and per cent changes in terminal hair (TH) density, and response rates. The trial was registered with clinicaltrials.gov (NCT04450589) and is completed. Findings: Forty-six subjects were enroled in the study, 23 allocated to the ALRV5XR treatment and 23 to the placebo group. Enrolment occurred from April 11 to October 23, 2018. Thirty-six subjects completed the trial (17 ALRV5XR, 19 placebo) and 11 subjects in each group were evaluable for TH outcomes. At 24 weeks, the absolute change in TH density improved by 21¢0 THs/cm 2 (95% CI: 9¢2À32¢8; p = 0¢0014), and the relative density increased by 16¢4% (95% CI: 7¢4%À25¢5%; p = 0¢0012). The odds ratio for being a responder ( 0 change) was 87¢4. TH density increased linearly and was not affected by HN, FST, ethnicity, age, or body mass index. All subjects in the ALRV5XR group responded to treatment while 81¢8% of the placebo group decreased TH density. ALRV5XR induced statistically significant changes in both decrease in vellus hair (VH) density as well as in concomitant increase of the TH/VH ratio when compared to placebo. ALRV5XR was well tolerated, and no adverse events were observed. Interpretation: ALRV5XR treatment resulted in clinically significant TH regrowth in men with AGA. Furthermore, it appeared to reverse the characteristic hair miniaturisation seen in this condition. When compared to results of published trials of standard therapy, ALRV5XR showed a multi-fold increase both in efficacy and in response rates. In addition, the continuance of TH regrowth from 12 to 24 weeks suggests that the normal structure and function of non-productive telogen follicles is restored and that a normal hair phenotype may be attained by extended ALRV5XR treatment. Funding: Arbor Life Labs.

show abstract

“…Additionally, the introduction of PRP improved hair regrowth by autologous human follicle MSC therapy in androgenetic alopecia [ 84 ]. The effects of autologous non-activated PRP and activated PRP in wound healing and hair regrowth were evaluated [ 85 ], and in 2021, the Academy of International Regenerative Medicine and Surgery Societies (AIRMESS) recommendations on the use of platelet-rich plasma (PRP) and autologous stem cell-based therapy (ASC-BT) in androgenetic alopecia and wound healing were released [ 86 ].…”

Section: Mesenchymal Stem Cell Therapy (Msct)mentioning

confidence: 99%

Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints

Kim¹,

Kim

Hong³

et al. 2021

Stem Cell Res Ther

View full text Add to dashboard Cite

Allergic diseases are immune-mediated diseases. Allergies share a common immunopathogenesis, with specific differences according to the specific disease. Mesenchymal stem/stromal cells (MSCs) have been applied to people suffering from allergic and many other diseases. In this review, the immunologic roles of MSCs are systemically reviewed according to disease immunopathogenesis from a clinical viewpoint. MSCs seem to be a promising therapeutic modality not only as symptomatic treatments but also as causative and even preventive treatments for allergic diseases, including atopic dermatitis and chronic urticaria.

show abstract

AIRMESS – Academy of International Regenerative Medicine & Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous stem cell-based therapy (ASC-BT) in androgenetic alopecia and wound healing

Cited by 22 publications

References 38 publications

Adipose mesenchymal stem cells combined with platelet-rich plasma accelerate diabetic wound healing by modulating the Notch pathway

Adipose mesenchymal stem cells combined with platelet-rich plasma accelerate diabetic wound healing by modulating the Notch pathway

Safety and efficacy of ALRV5XR in men with androgenetic alopecia: A randomised, double-blinded, placebo-controlled clinical trial

Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints

Contact Info

Product

Resources

About